Mackenzie Wolfe
Psychiatric/Mental Health · Reno, NVNPI 1770296345
Payments from drug & device makers
Across 36 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$285
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$156
- E.r. Squibb & Sons, L.L.C.$56
- Vanda Pharmaceuticals Inc.$37
- Luye Pharma (USA) Ltd.$26
- Axsome Therapeutics, Inc.$22
- plus $88 from 5 others
What the payments were for
- Food & beverage$671100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $285 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $156 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Luye Pharma (USA) Ltd. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
How this compares
$671 in reported general payments places this provider in the 45th percentile of 362 psychiatric/mental health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 19 | $509 |
| Hydroxyzine Pamoate | 29 | $499 |
| Quetiapine Fumarate | 23 | $237 |
| Risperidone | 20 | $197 |
| Gabapentin | 21 | $175 |
| Trazodone Hcl | 31 | $117 |
| Buspirone Hcl | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Reno
- Okechukwu OlisaReno$7K
- Kaiwen JiangReno$6K
- Alana RogneReno$6K
- Doris AnukamReno$5K
- Megan SeivertReno$4K
- Denis WilliamsReno$4K
- Nathanael MellumReno$3K
- Jacqueline WilliamsReno$3K
- Michelle GiddingsLas Vegas$131K
- Patrick ApiladoLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.